Evelyn Worthington

Publication Activity (10 Years)

Years Active: 2020-2021
Publications (10 Years): 6

Top Topics

Multiple Sclerosis

Top Venues

Journal of comparative effectiveness research

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, Paul Spin, Susan Lavinia Greco, Chris Cameron, Róisín Brennan, Frank Dahlke, Nicholas Adlard
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses. Current medical research and opinion 37 (11) (2021)
Imtiaz A Samjoo, Evelyn Worthington, Susan Lavinia Greco, Melody Zhao, Chris Cameron, Dieter A Häring, Dee Stoneman, Luisa Klotz, Nicholas Adlard
Letter in reply. Journal of comparative effectiveness research 10 (17) (2021)
Imtiaz A Samjoo, Evelyn Worthington, Susan Lavinia Greco, Melody Zhao, Chris Cameron, Dieter A Häring, Dee Stoneman, Luisa Klotz, Nicholas Adlard
Efficacy classification of modern therapies in multiple sclerosis. Journal of comparative effectiveness research 10 (6) (2021)
Imtiaz A Samjoo, Evelyn Worthington, Susan Lavinia Greco, Melody Zhao, Chris Cameron, Dieter A Häring, Dee Stoneman, Luisa Klotz, Nicholas Adlard
Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. Journal of comparative effectiveness research 9 (18) (2020)
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, Chris Cameron, Richard Nicholas, Frank Dahlke, Nicholas Adlard
The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. Current medical research and opinion 36 (7) (2020)
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, Chris Cameron, Richard Nicholas, Nicolas Rouyrre, Frank Dahlke, Nicholas Adlard
Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. Current medical research and opinion 36 (7) (2020)